Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive randomized trial of investigational therapeutics for hospitalized COVID-19 patients
2020-003278-37Phase 2Completed
- Sponsor
- Regents of the University of Minesota
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Ensovibep + SOC, AZD7442 + SOC and Placebo + SOC (3 arms). Primary endpoints: Time to sustained recovery and Ordinal outcomes for early futility assessments. Started Aug 2020; status: completed.
02
Drugs
ensovibeptixagevimab + cilgavimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-003278-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003278-37.